Jakarta, CNN Indonesia —
Pfizer book profit net of US$5.6 billion or equivalent to Rp. 81.1 trillion (assuming an exchange rate of Rp. 14,491 per US dollar) in the second quarter of 2021. This profit rose 59 percent from the same period last year.
Meanwhile, the drug company that made the COVID-19 vaccine recorded a 92 percent increase in revenue to US$19 billion or equivalent to Rp275 trillion.
Quoted from AFP, the company estimates it can book revenues of US$33.5 billion or around Rp485 trillion from the delivery of 2.1 billion doses of the COVID-19 vaccine.
The drugmaker from the United States has partnered with a German company, BioNTech to make a COVID-19 vaccine.
The sale results make the company lift its profit and revenue prospects throughout 2021. Pfizer Chief Executive Albert Bourla said more than one billion doses of the vaccine have been shipped to various countries.
“The speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 is unprecedented,” he said, Wednesday (28/7).
Pfizer said its pre-tax profit margin on sales of its Covid-19 vaccine was around 20 percent, the same as previous estimates.
Pfizer has launched a clinical study into a possible third dose of the Covid-19 vaccine as a booster shot. Bourla said such a driver could be a lasting revenue stream for the company.
US health officials have so far not endorsed a third injection for the broad population, but officials are studying the need for a third injection in immunocompromised people.
(age / eight)
– .
